COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Blood. 2021 Jul 1;137(26):3670-3673. doi: 10.1182/blood.2021011548.

Authors

Gloria F Gerber¹, Xuan Yuan¹, Jia Yu¹, Benjamin A Y Cher², Evan M Braunstein¹, Shruti Chaturvedi¹, Robert A Brodsky¹

Affiliations

¹ Division of Hematology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD; and.
² University of Michigan Medical School, Ann Arbor, MI.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural

MeSH terms

2019-nCoV Vaccine mRNA-1273
Adult
Anemia, Hemolytic / etiology*
Anemia, Hemolytic / prevention & control
Antibodies, Monoclonal, Humanized / therapeutic use
BNT162 Vaccine
Binding, Competitive
COVID-19 Vaccines / adverse effects*
COVID-19*
Clone Cells
Complement Factor D / antagonists & inhibitors
Complement Factor H / metabolism
Complement Inactivating Agents / therapeutic use
Complement Pathway, Alternative / drug effects*
Erythrocytes / drug effects
Female
Hemoglobinuria, Paroxysmal / blood*
Hemoglobinuria, Paroxysmal / drug therapy
Hemolysis / drug effects*
Heparitin Sulfate / metabolism
Humans
Male
Middle Aged
Protein Subunits
SARS-CoV-2*
Spike Glycoprotein, Coronavirus / adverse effects*
Spike Glycoprotein, Coronavirus / metabolism
Spike Glycoprotein, Coronavirus / pharmacology

Substances

Antibodies, Monoclonal, Humanized
CFH protein, human
COVID-19 Vaccines
Complement Inactivating Agents
Protein Subunits
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Complement Factor H
Heparitin Sulfate
ravulizumab
Complement Factor D
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine

Grants and funding